phenytoin has been researched along with Local Neoplasm Recurrence in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether levetiracetam is an alternative to fosphenytoin to control Benzodiazepine Refractory Status Epilepticus (BRSE) in pediatric population and also to compare the acute drug related side-effects and ventilation requirement among the both arms of anti-epileptic drug therapy." | 9.34 | Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus. ( Kandasamy, S; Krishnamoorthi, N; Nalisetty, S; Sangaralingam, T; Sridharan, B; Vijayakumar, V, 2020) |
| "Agranulocytosis is a rare side effect of phenytoin treatment." | 7.68 | Phenytoin-induced agranulocytosis: a nonimmunologic idiosyncratic reaction? ( McClune, GL; Sharafuddin, MJ; Spanheimer, RG, 1991) |
| "Levetiracetam reportedly has similar efficacy and higher safety for SE; however, evidence to support its use for adult SE is lacking." | 7.01 | Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-inferiority designed randomized control trial. ( Asami, M; Egawa, S; Hoshiyama, E; Inoue, Y; Kaneko, J; Kimura, A; Kondo, Y; Maruo, K; Marushima, A; Nakamura, K; Takahashi, Y; Yamada, T; Yonekawa, C, 2021) |
| "To determine whether levetiracetam is an alternative to fosphenytoin to control Benzodiazepine Refractory Status Epilepticus (BRSE) in pediatric population and also to compare the acute drug related side-effects and ventilation requirement among the both arms of anti-epileptic drug therapy." | 5.34 | Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus. ( Kandasamy, S; Krishnamoorthi, N; Nalisetty, S; Sangaralingam, T; Sridharan, B; Vijayakumar, V, 2020) |
| "Agranulocytosis is a rare side effect of phenytoin treatment." | 3.68 | Phenytoin-induced agranulocytosis: a nonimmunologic idiosyncratic reaction? ( McClune, GL; Sharafuddin, MJ; Spanheimer, RG, 1991) |
| "Levetiracetam reportedly has similar efficacy and higher safety for SE; however, evidence to support its use for adult SE is lacking." | 3.01 | Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-inferiority designed randomized control trial. ( Asami, M; Egawa, S; Hoshiyama, E; Inoue, Y; Kaneko, J; Kimura, A; Kondo, Y; Maruo, K; Marushima, A; Nakamura, K; Takahashi, Y; Yamada, T; Yonekawa, C, 2021) |
| " Further detailed pharmacokinetic studies of irinotecan in patients receiving concomitant therapy with enzyme-inducing anticonvulsants are required so that rational dosing recommendations can be provided for this patient population." | 1.31 | Influence of phenytoin on the disposition of irinotecan: a case report. ( Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nalisetty, S | 1 |
| Kandasamy, S | 1 |
| Sridharan, B | 1 |
| Vijayakumar, V | 1 |
| Sangaralingam, T | 1 |
| Krishnamoorthi, N | 1 |
| Gartrell, BA | 1 |
| Roach, M | 1 |
| Retter, A | 1 |
| Sokol, GH | 1 |
| Del Priore, G | 1 |
| Scher, HI | 1 |
| Nakamura, K | 1 |
| Marushima, A | 1 |
| Takahashi, Y | 1 |
| Kimura, A | 1 |
| Asami, M | 1 |
| Egawa, S | 1 |
| Kaneko, J | 1 |
| Kondo, Y | 1 |
| Yonekawa, C | 1 |
| Hoshiyama, E | 1 |
| Yamada, T | 1 |
| Maruo, K | 1 |
| Inoue, Y | 1 |
| Bamberg, M | 1 |
| Tamulevicius, P | 1 |
| Streffer, C | 1 |
| Scherer, E | 1 |
| Murry, DJ | 1 |
| Cherrick, I | 1 |
| Salama, V | 1 |
| Berg, S | 1 |
| Bernstein, M | 1 |
| Kuttesch, N | 1 |
| Blaney, SM | 1 |
| Sharafuddin, MJ | 1 |
| Spanheimer, RG | 1 |
| McClune, GL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1b/2, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of SM88 in Patients With Prostate Cancer[NCT02796898] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for phenytoin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Humans; Levetiracetam; Neoplasm Recurrence, Local; Phenytoi | 2020 |
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Humans; Kaplan-Meier Estimate; Male; Methoxsalen; Mid | 2021 |
Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-inferiority designed randomized control trial.
Topics: Adult; Anticonvulsants; Diazepam; Humans; Japan; Levetiracetam; Multicenter Studies as Topic; Neopla | 2021 |
3 other studies available for phenytoin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
[Clinical experiences with the radiosensitizer Misonidazol (author's transl)].
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Dexamethasone; Drug Interactions; Esophageal Neoplasms; Ex | 1981 |
Influence of phenytoin on the disposition of irinotecan: a case report.
Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2002 |
Phenytoin-induced agranulocytosis: a nonimmunologic idiosyncratic reaction?
Topics: Agranulocytosis; Brain Neoplasms; Carcinoma, Squamous Cell; Chemical and Drug Induced Liver Injury; | 1991 |